97 related articles for article (PubMed ID: 24939214)
1. Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer.
Cao J; Zhang J; Wang Z; Wang B; Lv F; Wang L; Hu X
Cancer Chemother Pharmacol; 2014 Aug; 74(2):389-98. PubMed ID: 24939214
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
Zhou A; Zhang W; Chang C; Chen X; Zhong D; Qin Q; Lou D; Jiang H; Wang J
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1043-53. PubMed ID: 24043137
[TBL] [Abstract][Full Text] [Related]
3. Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study.
Chen Q; Tang L; Liu N; Han F; Guo L; Guo S; Wang J; Liu H; Ye Y; Zhang L; Liu L; Wang P; Li Y; He Q; Yang X; Tang Q; Li Y; Liang Y; Sun X; Xie C; Mo Y; Guo Y; Sun R; Mo H; Cao K; Guo X; Zeng M; Mai H; Ma J
Cancer Commun (Lond); 2018 Nov; 38(1):66. PubMed ID: 30382933
[TBL] [Abstract][Full Text] [Related]
4. Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy.
Kust D; Prpić M; Murgić J; Jazvić M; Jakšić B; Krilić D; Bolanča A; Kusić Z
Anticancer Res; 2014 Jun; 34(6):3177-84. PubMed ID: 24922691
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Burstein HJ; Elias AD; Rugo HS; Cobleigh MA; Wolff AC; Eisenberg PD; Lehman M; Adams BJ; Bello CL; DePrimo SE; Baum CM; Miller KD
J Clin Oncol; 2008 Apr; 26(11):1810-6. PubMed ID: 18347007
[TBL] [Abstract][Full Text] [Related]
6. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Bailey EB; Tantravahi SK; Poole A; Agarwal AM; Straubhar AM; Batten JA; Patel SB; Wells CE; Stenehjem DD; Agarwal N
Clin Genitourin Cancer; 2015 Jun; 13(3):e131-7. PubMed ID: 25497584
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy.
Fan M; Zhang J; Wang Z; Wang B; Zhang Q; Zheng C; Li T; Ni C; Wu Z; Shao Z; Hu X
Breast Cancer Res Treat; 2014 Jan; 143(1):141-51. PubMed ID: 24292957
[TBL] [Abstract][Full Text] [Related]
8. Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.
Xu RH; Shen L; Wang KM; Wu G; Shi CM; Ding KF; Lin LZ; Wang JW; Xiong JP; Wu CP; Li J; Liu YP; Wang D; Ba Y; Feng JP; Bai YX; Bi JW; Ma LW; Lei J; Yang Q; Yu H
Chin J Cancer; 2017 Dec; 36(1):97. PubMed ID: 29273089
[TBL] [Abstract][Full Text] [Related]
9. Famitinib in metastatic renal cell carcinoma: a single center study.
Zhang W; Zhou AP; Qin Q; Chang CX; Jiang HY; Ma JH; Wang JW
Chin Med J (Engl); 2013 Nov; 126(22):4277-81. PubMed ID: 24238512
[TBL] [Abstract][Full Text] [Related]
10. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
Terakawa T; Miyake H; Kusuda Y; Fujisawa M
Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
[TBL] [Abstract][Full Text] [Related]
13. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
Sella A; Hercbergs AH; Hanovich E; Kovel S
Chemotherapy; 2012; 58(3):200-5. PubMed ID: 22759787
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
Vahdat LT; Layman R; Yardley DA; Gradishar W; Salkeni MA; Joy AA; Garcia AA; Ward P; Khatcheressian J; Sparano J; Rodriguez G; Tang S; Gao L; Dalal RP; Kauh J; Miller K
Oncologist; 2017 Mar; 22(3):245-254. PubMed ID: 28220020
[TBL] [Abstract][Full Text] [Related]
15. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancer.
Sun B; Zhao X; Ding L; Meng X; Song S; Wu S
Oncotarget; 2016 Sep; 7(36):57894-57902. PubMed ID: 27506945
[TBL] [Abstract][Full Text] [Related]
17. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.
Fujiwara Y; Kiyota N; Chayahara N; Suzuki A; Umeyama Y; Mukohara T; Minami H
Invest New Drugs; 2012 Jun; 30(3):1055-64. PubMed ID: 21301929
[TBL] [Abstract][Full Text] [Related]
18. Pre-admission TSH levels predict long-term mortality in adults treated for hypothyroidism.
Akirov A; Shochat T; Shechvitz A; Shimon I; Diker-Cohen T; Robenshtok E
Endocrine; 2017 Dec; 58(3):481-487. PubMed ID: 29058108
[TBL] [Abstract][Full Text] [Related]
19. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
20. Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers.
Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
Thyroid; 2018 Apr; 28(4):445-453. PubMed ID: 29652597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
